Strategic Preclinical Research Service for Myxoma Virus Therapeutic & Diagnostic Solution

Overview

The Myxoma virus (MYXV) belongs to the Poxviridae family and falls under the Leporipoxvirus genus. This double-stranded DNA virus causes myxomatosis, which proves to be a deadly disease for European rabbits (Oryctolagus cuniculus). The virus originated in South American rabbits before scientists spread it to other regions such as Australia and Europe to use as a biological control for managing excessive rabbit populations. MYXV naturally targets rabbits as its primary host, but research shows it may have therapeutic applications for several human cancers. The virus enters cells through macropinocytosis and utilizes immune-modulatory proteins to dodge host immune defenses, which positions it as a prime option for tumor-selective virotherapy. The virus MYXV fails to replicate in most mammalian cells outside rabbits, which improves its safety during clinical research studies. Creative Biolabs offers a complete range of preclinical research services for MYXV, such as virus engineering and in vitro cytotoxicity assays, along with in vivo tumor models and immunological evaluations. The development and evaluation of MYXV-based oncolytic virotherapy and gene delivery systems represents our area of specialization. We provide specialized solutions to facilitate your translational research throughout proof-of-concept studies until advanced efficacy and safety evaluations.

Accelerated Myxoma Virus Preclinical Research Services

• For Therapeutics Development

In Vitro Antiviral Efficacy Assays

• Cytotoxicity Assays: MTT, MTS, or XTT Assays to measure cell viability and cytotoxicity after virus exposure.
• Viral Replication Assays: Quantification of viral titers through plaque assays or PCR to measure viral replication and spread in cell culture.
• Antiviral Effectiveness Assay: Determining the dose-response curve for antiviral activity and the selectivity index (SI) to assess the virus's ability to selectively target diseased cells over healthy ones.
• Infection Kinetics Assays: Tracking the viral infection cycle over time in cultured cells using fluorescence or real-time PCR.

In Vivo Efficacy Studies (Animal Models)

• Animal Model Selection: Use of syngeneic, xenograft, or genetically modified animal models (usually mice or rabbits) that mimic human diseases such as cancer or viral infections.
• Toxicity Studies: Safety Profile Evaluation: Identifying any adverse effects in animals treated with the virus. This could include weight loss, organ toxicity, or other physiological markers indicating damage.
• Pharmacokinetic Studies: Virus Distribution and Clearance: Using techniques like PCR or radiolabeled virus tracking to assess the distribution of the virus throughout the animal body, as well as its clearance rate.

• For Diagnostics Development

Antigen Detection Assays

• Immunohistochemistry (IHC): Detection of viral antigens directly in tissue sections using specific antibodies.
• Immunofluorescence Assay (IFA): Fluorescently-labeled antibodies are used to detect Myxoma virus antigens in infected cells.
• Lateral Flow Assays (LFAs): Like rapid tests for other infections (like COVID-19), LFAs can be developed to detect MYXV antigens in biological fluids (blood, saliva, etc.).

Nucleic Acid Detection Assays

• Real-Time PCR (qPCR): Quantitative PCR to measure the amount of MYXV in a sample. This is useful for tracking viral replication and assessing the efficacy of antiviral therapies in preclinical studies.
• In Situ Hybridization (ISH): A technique used to detect viral RNA within fixed tissues.
• Droplet Digital PCR (ddPCR): A more advanced version of qPCR that can provide absolute quantification of viral DNA/RNA in samples, offering higher sensitivity and precision for detecting low viral loads.

Antibody Detection Assays (Serology)

• Western Blot (Immunoblotting): A technique that identifies specific antibodies against viral proteins by electrophoretically separating the proteins, followed by probing with a secondary antibody that binds the host antibody.
• Neutralization Assays: This assay measures the ability of host serum antibodies to neutralize the infectivity of the Myxoma virus.
• Immunoprecipitation: A method where viral proteins are precipitated out of a sample using specific antibodies, followed by detection of host antibodies bound to those proteins.
• Serum Neutralization Test: The serum from a subject (animal or human) is tested for its ability to neutralize the infectivity of MYXV in vitro.

Request a Quote

Products for Myxoma Virus Research

Expression systems generate recombinant proteins of Myxoma virus for both research applications and diagnostic purposes. They include viral structural and immunomodulatory proteins. These proteins serve as essential tools for developing vaccines and conducting serological assays and immune response examinations. High-purity recombinant MYXV proteins provide dependable and consistent outcomes in experiments.

• Recombinant Myxoma Virus proteins or antigens

Get a Quote Today

Applications

Advantages

1. Comprehensive Expertise: Our virus research capabilities cover the entire spectrum of research from molecular cloning to viral engineering and from in vitro assays to in vivo animal studies.

2. Customizable Platforms: We develop research strategies for oncolytic viruses, antivirals, immunotherapies, and vaccine development that match client-specific needs.

3. Advanced Technologies: State-of-the-art methods like qPCR, flow cytometry, ELISA, and high-throughput screening deliver precise and consistent results.

4. Experienced Team: Top experts from virology, immunology, oncology, and molecular biology make up the multidisciplinary team.

FAQs